Brio Consultants LLC Buys New Stake in Johnson & Johnson (NYSE:JNJ)

Key Points

• Brio Consultants LLC acquired 2,016 shares of Johnson & Johnson stock, valued at approximately $334,000, during the first quarter.
• The company reported $2.77 earnings per share for the last quarter, exceeding expectations, and had a quarterly revenue of $23.74 billion.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, offering shareholders an annualized return of 3.13%.

Brio Consultants LLC bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 2,016 shares of the company's stock, valued at approximately $334,000.

A number of other hedge funds have also recently modified their holdings of JNJ. Conquis Financial LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $33,000. Bernard Wealth Management Corp. purchased a new position in Johnson & Johnson during the 4th quarter worth $36,000. Highline Wealth Partners LLC grew its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter worth $49,000. Finally, Capital A Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $50,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $166.18 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market cap of $399.84 billion, a P/E ratio of 17.77, a PEG ratio of 2.14 and a beta of 0.41. The company has a 50-day moving average of $156.36 and a two-hundred day moving average of $156.14. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.82 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on JNJ shares. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Bank of America lifted their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.